In conjunction with (i) the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, and (ii) the final terms of the ...

PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is ...

The panel unanimously ruled that the federal judge did not abuse his discretion when he approved the settlement and attorneys ...

Competing interests None declared. Patient consent Patient enrolled in the study signed the patient consent form approved by the Ethic Committee of Vall d’Hebron Hospital and by the Agencia Espaola ...

The Public-Private Partnership Unit (UKAS) will soon invite proposals for a transit system to help disperse traffic from the ...

Had they been successful the far right would have led the alpine nation's government for the first time. Now snap elections are likely, with the Freedom Party, founded by former Nazis, polling well ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed to establish a conclusive benefit.

Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating open-label extension in 1H'25; ...